VEDOLIZUMAB IS SUPERIOR TO ANTI-TUMOR NECROSIS FACTOR AGENTS AS A FIRST-LINE BIOLOGICAL AGENT BUT NOT AS A SECOND-LINE BIOLOGICAL AGENT IN MODERATE TO SEVERE ULCERATIVE COLITIS

被引：0
|
作者：
Pudipeddi, Aviv
Ko, Yanna
Paramsothy, Sudarshan
Leong, Rupert W.
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Fr519
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [11] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120
  • [12] Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis
    Birolo, Carolina
    Zannin, Maria Elisabetta
    Arsenyeva, Svetlana
    Cimaz, Rolando
    Miserocchi, Elisabetta
    Dubko, Margarita
    Deslandre, Chantal Job
    Falcini, Fernanda
    Alessio, Maria
    La Torre, Francesco
    Denisova, Ekaterina
    Martini, Giorgia
    Nikishina, Irina
    Zulian, Francesco
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (11) : 2068 - 2073
  • [13] UTILISATION AND IMPACT OF IMMUNOMODULATOR CO-THERAPY WITH FIRST-LINE AND SECOND-LINE ANTITUMOUR NECROSIS FACTOR AGENTS IN CROHN'S DISEASE AND ULCERATIVE COLITIS
    Pudipeddi, Aviv
    Paramsothy, Sudarshan
    Leong, Rupert
    GUT, 2022, 71 : A150 - A151
  • [14] SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS
    Chaaban, Lara
    Huang, Jane
    Melia, Joanna
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S82 - S83
  • [15] Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
    Calmejane, L.
    Reenaers, C.
    Amiot, A.
    Nuzzo, A.
    Vuitton, L.
    Altwegg, R.
    Guillo, L.
    Wils, P.
    Roblin, X.
    Le Cosquer, G.
    Simon, M.
    Benezech, A.
    Laharie, D.
    Fumery, M.
    Buisson, A.
    Charkaoui, M.
    Nancey, S.
    Sabra, G.
    Geyl, S.
    Coffin, B.
    Cavicchi, M.
    Le Berre, C.
    Goutorbe, F.
    Bouguen, G.
    Vidon, M.
    Christmann, P. Y.
    Kirchgesner, J.
    Uzzan, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I699 - I699
  • [16] Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis
    Volonaki, Eleni
    Mutalib, Mohamed
    Kiparissi, Fevronia
    Shah, Neil
    Lindley, Keith J.
    Elawad, Mamoun
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (12) : 1425 - 1428
  • [17] Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
    Hye Kyung Hyun
    Hyun-Soo Zhang
    Jongwook Yu
    Eun Ae Kang
    Jihye Park
    Soo Jung Park
    Jae Jun Park
    Tae Il Kim
    Won Ho Kim
    Jae Hee Cheon
    BMC Gastroenterology, 22
  • [18] Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment
    Hyun, H. K.
    Yu, J.
    Kang, E. A.
    Park, J.
    Park, S. J.
    Park, J. J.
    Kim, T. I.
    Kim, W. H.
    Cheon, J. H.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S531 - S531
  • [19] Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment
    Hyun, Hye Kyung
    Zhang, Hyun-Soo
    Yu, Jongwook
    Kang, Eun Ae
    Park, Jihye
    Park, Soo Jung
    Park, Jae Jun
    Kim, Tae Il
    Kim, Won Ho
    Cheon, Jae Hee
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [20] Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease
    Bressler, Brian
    Yarur, Andres
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Saha, Sumit
    Kifnidi, Christina
    Demuth, Dirk
    Patel, Haridarshan
    Mantzaris, Gerassimos J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S373 - S373
12345